Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H12F2N6 |
| Molecular Weight | 374.3463 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(C1=NN=C2C=CC(=NN12)C3=CC=NC=C3)C4=CC5=C(C=C4)N=CC=C5
InChI
InChIKey=KOAWAWHSMVKCON-UHFFFAOYSA-N
InChI=1S/C20H12F2N6/c21-20(22,15-3-4-16-14(12-15)2-1-9-24-16)19-26-25-18-6-5-17(27-28(18)19)13-7-10-23-11-8-13/h1-12H
| Molecular Formula | C20H12F2N6 |
| Molecular Weight | 374.3463 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1372 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37260332/ |
250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
JNJ-38877618 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5684 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37260332/ |
250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
JNJ-38877618 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37260332/ |
250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
JNJ-38877618 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 17:24:47 GMT 2025
by
admin
on
Tue Apr 01 17:24:47 GMT 2025
|
| Record UNII |
E0B2IZB5H5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
943540-74-7
Created by
admin on Tue Apr 01 17:24:47 GMT 2025 , Edited by admin on Tue Apr 01 17:24:47 GMT 2025
|
PRIMARY | |||
|
C148537
Created by
admin on Tue Apr 01 17:24:47 GMT 2025 , Edited by admin on Tue Apr 01 17:24:47 GMT 2025
|
PRIMARY | |||
|
E0B2IZB5H5
Created by
admin on Tue Apr 01 17:24:47 GMT 2025 , Edited by admin on Tue Apr 01 17:24:47 GMT 2025
|
PRIMARY | |||
|
57654476
Created by
admin on Tue Apr 01 17:24:47 GMT 2025 , Edited by admin on Tue Apr 01 17:24:47 GMT 2025
|
PRIMARY | |||
|
300000042483
Created by
admin on Tue Apr 01 17:24:47 GMT 2025 , Edited by admin on Tue Apr 01 17:24:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Janssen-Cilag; Mechanism of Action: Proto oncogene protein c met inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Cancer; Most Recent Event: 15 Oct 2013 Janssen-Cilag plans a phase I trial for Healthy volunteers in the UK (NCT01964872)
|